• Quantum Diamonds

  Participated · Grant · Nov 2023

  QuantumDiamonds develops and plans to manufacture advanced measurement and test systems for the semiconductor industry using novel quantum sensors that enable high-resolution, three-dimensional inspection of modern chips. The company is building the first production site for these quantum-sensor-based systems in the EU, with an announced investment plan of €152 million. It secured a €76 million direct grant approved by the European Commission and expects additional public support from the German federal and Bavarian state governments. QuantumDiamonds has made operational commitments tied to the public support, including prioritizing orders during shortages, offering early access to parts of the facility to startups and academic labs, and sharing excess project-related profits with Germany. The project is positioned as contributing to European semiconductor supply security and to strengthening the EU value chain under the European Chips Act.

• Pieris Pharmaceuticals

  Led · Equity · Feb 2022

  Pieris is developing novel biotherapeutics based on its proprietary Anticalin® technology platform, with programs targeting cancer and lung diseases such as idiopathic pulmonary fibrosis. Its most advanced proprietary program is PRS-220, an inhalable Anticalin®-based therapeutic being developed to treat SARS-CoV-2-induced lung injury and fibrotic lung changes following COVID-19. Pieris intends to expand clinical investigation of PRS-220 beyond idiopathic pulmonary fibrosis and has stated plans to initiate clinical development as early as this year. The company received public funding to accelerate clinical development of PRS-220, enabling faster progression toward regulatory maturity. Pieris emerged as a spin-off from the Technical University of Munich in 2001 and is based in Hallbergmoos near Munich. Stephen S. Yoder is named in the article as President and CEO and commented on the program and funding.

No current team members are available.